COVID-19 Assay & Research


Our Best-in-Class COVID-19 Solutions

Antibody Detection

COVID-19 Surveillance

Vaccine and Therapeutic R&D

New Products

Latest News

COVID-19 Updates from Bio-Rad

We are helping customers, colleagues, and the global community during this health crisis. Learn How »

Coronavirus Research Webinars

Upcoming Webinars

Qian Gao, PhD, Vanitha Margan, and Brett Houser

How to Develop a New Multiplex SARS‑CoV‑2 Variant Neutralizing Antibody Assay in a Day​
Wednesday, June 15 at 9:00 AM PT and​
Tuesday, June 21 at 8:30 PM PT ​

In this webinar, we will discuss the utilization of Bio‑Plex Pro Human SARS‑CoV‑2 Neutralization Custom Assay Developer Kit to efficiently develop new variant assays for the detection and determination of percentage inhibition of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) neutralizing antibodies with affinity to SARS‑CoV‑2 variants.​

You will learn about:

  • Competitive multiplex immunoassay technology (format) in SARS‑CoV‑2 neutralizing antibody assay development​
  • Conjugating a SARS‑CoV‑2 variant antigen to a magnetic bead ​
  • Developing a SARS‑CoV‑2 neutralizing antibody assay using Bio‑Plex SARS‑CoV‑2 Neutralization Antibody Custom Assay Developer Kit ​
  • Determination of percent inhibition of SARS‑CoV‑2 neutralizing antibodies​
Register for Webinar

Past Webinars

Role of Aberrant Cytokine Activity in the Host Immune Response to COVID‑19

Immunological Response Factors to SARS‑CoV‑2 in Acquired Immunity
Tuesday, February 9 at 9:00AM PDT

In this webinar, we will be discussing the immune response to SARS‑CoV2, both in the context of natural exposure to the virus as well as induced immunity from vaccination. We will also investigate the relationship between symptom severity and the longevity of acquired immunity.

You will learn about:

  • SARS‑CoV‑2 virion and ACE2 binding
  • Initiation of the adaptive response
  • T‑ and B‑lymphocyte maturity
  • B‑lymphocyte conversion to memory and plasma cells
  • Factors that affect the duration of acquired immunity

Role of Aberrant Cytokine Activity in the Host Immune Response to COVID‑19

The Role of Aberrant Cytokine Activity in the Host Immune Response to COVID‑19

In this webinar, we will be discussing early research and nascent hypotheses regarding the pathophysiology of SARS‑CoV‑2 induced COVID-19 disease by evaluating cytokine and chemokine profiles, the role of chronic inflammation in comorbidities, and the arc of immune resolution of historical virulent pathogens, such as SARS and MERS.

Featured Article"Aberrant Cytokine Activity in the Host Immune Response to COVID‑19 Leads to Cytokine Release Syndrome"

Discover why the potential link between cytokine release syndrome (CRS) and COVID‑19‑related deaths warrants further investigation.

Real-Time PCR in Infectious Disease

Real-Time PCR in Infectious Disease

In this webinar, learn more about:

  • Characterizing COVID-19 using qPCR
  • Accurately select your internal control
  • Exploring 1-step v. 2-step in sample preparation

Live Expert Panel Discussion on the relevance of COVID-19 testing

Live Expert Panel Discussion on the Relevance of COVID-19 Testing with Droplet Digital PCR

This webinar will discuss:

  • Comparison of ddPCR to RT-PCR technologies
  • Performance data from validation studies
  • Case studies with hospital network
  • The next wave of SARS-CoV-2 assays for vaccine development and surveillance
  • Pharma needs for vaccine development

Bio-Plex Pro Human Immunotherapy Panel to Elucidate Changes in T Cells

Using Bio-Plex Multiplex Immunoassays to Monitor T Cell Response to Anti‑PD1 Therapy

In this webinar you learn how to:

  • Quickly monitor 20 cytokine profiles to assess patient response to immunotherapy
  • Confidently evaluate safety profiles associated with biologics
  • Measure cytokine overproduction associated with cytokine release syndrome
  • Perform powerful analysis with multitimepoint, multipatient, and multidose measurements all on one 96-well plate

On-Demand Expert Panel Discussion on COVID-19

On-Demand Expert Panel Discussion on COVID-19 with Droplet Digital PCR and Antibody Testing

This webinar provides an overview of the approaches that Bio-Rad is taking in the battle against COVID‑19:

  • Detection and diagnosis with Droplet Digital PCR
  • Confirming with ddPCR testing to determine viral load and post-infection clearance
  • Surveillance and diagnosis with serology testing to ensure adequate immune response and immunity

On-Demand Expert Panel Discussion on COVID-19

5th Droplet Digital PCR (ddPCR) Asia Pacific Symposium 2020

Learn from our panel of experts as they discuss how one of the most exciting technologies in biomedical science — Droplet Digital PCR — is revolutionizing nucleic acid detection and quantitation in the following topics:

  • COVID-19 detection — detection of SARS-CoV-2 to increase confidence and reduce false negative test results
  • Cell and Gene therapies — accelerating the development of new generation of therapies
  • Liquid biopsy — rapid implementation of precise, personalised assays allowing clinicians to closely monitor patient progress and tailor treatment with confidence

Scientist working on a diagnostics kit

Coronavirus Outbreak: The Singapore StoryThe Development of a Locally Made Diagnostic Kit to Combat the COVID-19 Pandemic

Learn how Bio-Rad helped the Singapore Agency for Science, Technology, and Research (A*STAR) develop their SARS-CoV-2 test kit for use in hospitals across Singapore.

COVID-19 Resources

2019-20 Coronavirus Pandemic (COVID-19; 2019-nCoV)

The novel coronavirus identified as the causative agent of pneumonia cases first detected in Wuhan City, China in December, 2019, was officially designated as SARS-CoV-2. On March 11, 2020, WHO declared COVID-19 a global pandemic. For the latest information on the Novel Coronavirus COVID-19 / 2019-nCoV pandemic, visit the World Health Organization website: > Emergencies > Diseases > Coronavirus disease 2019

The US Centers for Disease Control and Prevention provides valuable information for US and global citizens. See the CDC website for the 2019 Novel Coronavirus Situation Summary, guidance for travelers, information for healthcare and public health professionals, guidance for laboratory professionals, background information, and the latest news: > 2019 Novel Coronavirus

Although there are no clinical diagnostics for coronavirus 2019-nCoV currently approved by the US Food & Drug Administration (FDA), on February 4th, 2020, the FDA issued an Emergency Use Authorization to temporarily expand the use of RT-PCR assays for the identification of 2019-nCoV. For updates, see the US Food & Drug Administration website: > Medical Countermeasures Initiative (MCMi) > Novel Coronavirus (2019-nCoV) > Medical Countermeasures Initiative (MCMi) > Emergency Use Authorization